how can we improve responses to immunotherapy in patients with bladder cancer?
Published 2 years ago • 205 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
2:05
improving responses to trimodality therapy in patients with muscle-invasive bladder cancer
-
2:38
improving responses to immunotherapy in bladder cancer
-
4:13
using the urinary microbiome to predict bcg therapy responses in bladder cancer patients.
-
1:10
the difficulties in treating bladder cancer with immunotherapy
-
1:14
how can we continue the success of checkpoint inhibitors for bladder cancer treatment?
-
3:27
improving anti-pd-1/pd-l1 therapy for localized bladder cancer
-
2:35
genomic determinants of response to tmt for patients with muscle-invasive bladder cancer
-
53:15
will new antibody drug conjugates cure bladder cancer?
-
4:42
bladder-sparing trimodality therapy for muscle-invasive bladder cancer
-
2:40
combining agents to improve response rates in genitourinary cancer
-
3:31
the use of immunotherapy as a first-line therapy for bladder cancer
-
47:59
advances in bladder cancer immunotherapy, with dr. arjun balar
-
30:30
treatment talks | question and answer about immunotherapy
-
1:10
highlights in bladder cancer from asco 2022
-
34:39
bladder cancer and immunotherapy with dr. arjun balar
-
1:46
dr. iyer on advice for physicians using immunotherapy in bladder cancer
-
26:56
bladder cancer immunotherapy: building on a history of immune response
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
7:32
the promise of immunotherapy in bladder cancer